Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the third quarter ended September 30, 2022 and provided a corporate update
By Novan, Inc.
Published - Nov 14, 2022, 07:08 AM ET
Last Updated - Mar 28, 2024, 11:11 AM EDT
– Rhofade prescriptions increased 37% for third quarter year-to-date from prior year –
– Continued progress toward submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeted around the end of 2022 –
– Company to host conference call today at 8:30 a.m. ET –
DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the third quarter ended September 30, 2022 and provided a corporate update. The Company will host a conference call and webcast, today, November 14, 2022, at 8:30 a.m. ET (details below).
